CJC-1295 (without DAC) and Finasteride Interaction

Monitor
Mechanism-based 51% confidence

CJC-1295 (without DAC) and Finasteride have an interaction requiring monitoring for interaction with 51% confidence. Both CJC-1295 (without DAC) and Finasteride can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. These compounds primarily affect different organ systems.

Compound Profiles

CJC-1295 (without DAC)

Short-Acting Growth Hormone Releasing Hormone Analog

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Half-life: 30 minutes - 2 hours Typical dose: 100-300mcg per injection growth hormone, weight loss
ghrh receptor carcinogenic riskestrogenicinsulin disruptingteratogenic
View full profile

Finasteride

5-Alpha Reductase Inhibitor | DHT Blocker for Hair Loss & BPH

Finasteride competitively and selectively inhibits the Type II isoform of the enzyme 5-alpha reductase, which is predominantly found in hair follicles, the prostate, and the liver. This enzyme converts testosterone into dihydrotestosterone (DHT).

Half-life: 6-8 hours (DHT suppression persists ~24 hours) Typical dose: 1mg/day (hair loss) or 5mg/day (BPH) hair loss
5 alpha reductase estrogenichepatotoxicteratogenic
View full profile

Combined Organ Load

GI Tract
low
Pituitary
low
Skin
low

Shared Safety Flags

2x 2 estrogenic compounds (CJC-1295 (without DAC), Finasteride). Combined estrogen elevation — monitor E2 and consider aromatase inhibitor.
2x 2 compounds share the teratogenic safety flag (CJC-1295 (without DAC), Finasteride). Monitor accordingly.

Frequently Asked Questions

Can I take CJC-1295 (without DAC) with Finasteride?

Yes, but with caution. Both CJC-1295 (without DAC) and Finasteride can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. Regular monitoring is advised.

Is CJC-1295 (without DAC) and Finasteride safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: estrogenic, teratogenic. Monitor accordingly.

What are the interactions between CJC-1295 (without DAC) and Finasteride?

Both CJC-1295 (without DAC) and Finasteride can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed. This assessment has 51% confidence and is inferred from pharmacological mechanism analysis.

How should I time CJC-1295 (without DAC) and Finasteride?

CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and Finasteride has a half-life of 6-8 hours (DHT suppression persists ~24 hours). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: CJC-1295 (without DAC) vs Finasteride

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.